Search - tctmd.com

Displaying 1 - 20 of 96

Sort: Relevancy | Date

News Daily News

Top Structural Heart News of 2023

Todd Neale

January 02, 2024

News Daily News

SWEDEHEART Affirms SAVR’s Long-term Benefits in Young, Low-Risk AS

L.A. McKeown

November 30, 2021

News Daily News

Infective Endocarditis Rare After AVR, but Often a Killer When It Occurs

Michael O'Riordan

October 01, 2021

News Daily News

EXPLANT-TAVR: Data Spur Conversation About Balancing Risk and Lifetime Management

L.A. McKeown

September 22, 2021

Excluded from Pivotal Trials, Low-risk Complex Patients Warrant Caution

News Daily News

Excluded From Pivotal Trials, Low-risk Complex AS Patients Warrant Caution

L.A. McKeown

January 22, 2021

News Daily News

TAVR and Infective Endocarditis—Two Studies Address a Shifting Landscape

Caitlin E. Cox

September 14, 2020

News Daily News

Should Guidelines Support TAVR for Low-Risk Patients? Two Views

L.A. McKeown

August 17, 2020

News Daily News

Oral Anticoagulation Post-AVR Safe but Not Routinely Needed: PARTNER II

Caitlin E. Cox

August 27, 2019

News Daily News

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

Caitlin E. Cox

August 21, 2019

News Daily News TCT 2018

High Mortality but Durable Results With Valve-in-Valve TAVR

Michael O'Riordan

September 23, 2018

News Daily News

Sex Differences Diminish With Third-Generation TAVR Device

L.A. McKeown

January 05, 2018

News Daily News

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

Todd Neale

March 15, 2017

News Daily News

TAVR: Miracle for Some, but No Improvements in Quality of Life for Others

Yael L. Maxwell

December 22, 2016

News Daily News

TAVR 3 年后瓣膜性能持稳，大多数死亡非心脏相关：FRANCE 2 登记表

Caitlin E. Cox

October 04, 2016

News Daily News

Registro FRANCE 2: 3 Años Después de una TAVR, el Rendimiento de la Válvula se Mantiene y casi Toda la Mortalidad es No Cardíaca

Caitlin E. Cox

October 04, 2016

News Daily News

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Caitlin E. Cox

October 04, 2016

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

News Daily News

Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns

Shelley Wood

September 13, 2016

News Daily News

Riesgo de ACV con TAVR: Una Revisión en Profundidad de los Datos del PARTNER y CoreValve Revela Oportunidades e Incógnitas

Shelley Wood

September 13, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

Advertisement

Top Structural Heart News of 2023

SWEDEHEART Affirms SAVR’s Long-term Benefits in Young, Low-Risk AS

Infective Endocarditis Rare After AVR, but Often a Killer When It Occurs

EXPLANT-TAVR: Data Spur Conversation About Balancing Risk and Lifetime Management

Excluded From Pivotal Trials, Low-risk Complex AS Patients Warrant Caution

TAVR and Infective Endocarditis—Two Studies Address a Shifting Landscape

Should Guidelines Support TAVR for Low-Risk Patients? Two Views

Oral Anticoagulation Post-AVR Safe but Not Routinely Needed: PARTNER II

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

High Mortality but Durable Results With Valve-in-Valve TAVR

Sex Differences Diminish With Third-Generation TAVR Device

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

TAVR: Miracle for Some, but No Improvements in Quality of Life for Others

TAVR 3 年后瓣膜性能持稳，大多数死亡非心脏相关：FRANCE 2 登记表

Registro FRANCE 2: 3 Años Después de una TAVR, el Rendimiento de la Válvula se Mantiene y casi Toda la Mortalidad es No Cardíaca

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns

Riesgo de ACV con TAVR: Una Revisión en Profundidad de los Datos del PARTNER y CoreValve Revela Oportunidades e Incógnitas

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content